A genetically engineered fusion protein consisting of a human/mouse chimeric anti-ganglioside GD2 antibody (chl4.18) and recombinant human interleukin 2 (rhIL-2) was tested for its ability to target rhIL-2 to tumor sites and stimulate immune effector cells sufficiently to achieve effective tumor cell lysis in vivo. The chl4.18-IL-2 fusion protein proved more effective than equivalent doses of rhIL-2 in suppressing dissemination and growth of human neuroblastoma in an experimental hepatic metastases model of scid (severe combined immunodeficiency) mice reconstituted with human lymphokine-activated killer cells. The chl4.18-IL-2 fusion protein was also more proficient than equivalent doses of rhIL-2 in prolonging the life-span of these animals. This recombinant antibody-cytokine fusion protein may prove useful for future treatment ofGD2-expressing human tumors in an adjuvant setting.
(rhIL-2) was tested for its ability to target rhIL-2 to tumor sites and stimulate immune effector cells sufficiently to achieve effective tumor cell lysis in vivo. The chl4.18-IL-2 fusion protein proved more effective than equivalent doses of rhIL-2 in suppressing dissemination and growth of human neuroblastoma in an experimental hepatic metastases model of scid (severe combined immunodeficiency) mice reconstituted with human lymphokine-activated killer cells. The chl4.18-IL-2 fusion protein was also more proficient than equivalent doses of rhIL-2 in prolonging the life-span of these animals. This recombinant antibody-cytokine fusion protein may prove useful for future treatment ofGD2-expressing human tumors in an adjuvant setting.
Cancer immunotherapy with interleukin 2 (IL-2) has found increased use during the past few years because of its stimulatory effects on a wide range of immune effector cells and the availability of large quantities of recombinant human IL-2 (rhIL-2) (1-5). Stimulation of peripheral blood lymphocytes by IL-2 in vitro and in vivo produced lymphokineactivated killer (LAK) cells, derived mainly from natural killer (NK) cells, that were applied in clinical trials that produced responses in some patients with melanoma and renal carcinoma (1, 2) . In pediatric neuroblastoma, systemic therapy with rhIL-2 resulted in only modest regressions of metastases with marginal clinical improvement (6, 7) . This treatment did, however, stimulate the potent generation of NK and cytotoxic T cells, as well as functionally active LAK cells (4, 7) .
Clinical studies indicated that prolonged partial and complete remissions ofpediatric neuroblastoma could be induced by both murine anti-GD2 antibody 14.G2a (8) and its human/ chimeric variant chl4.18 (9) . Prior preclinical experiments had shown that both of these antibodies could effectively mediate antibody-dependent cellular cytotoxicity (ADCC) by peripheral blood mononuclear cells (10, 11) . This ADCCmediated killing of neuroblastoma cells could be further augmented by CD56+ NK cells that were produced in increased amounts by IL-2 treatment of pediatric neuroblastoma patients (12) . Furthermore, therapy of neuroblastoma patients with rhIL-2 and monoclonal antibody (mAb) 14.G2a generated conditions within the peripheral blood of these patients that enabled their own lymphocytes to mediate ADCC sufficiently to effectively kill human neuroblastoma cells in vitro (13) . Taken together, these findings provided a rationale for evaluating the efficacy of an anti-GD2-IL-2 fusion protein in killing human neuroblastoma cells in vivo.
In the studies described here, we used a genetically engineered fusion protein, ch14.18-IL-2, consisting of chimeric anti-ganglioside GD2 antibody (chl4.18) and rhIL-2. This chl4.18-IL-2 fusion protein was shown previously to target IL-2 to tumor cells and to stimulate T-cell-mediated killing of autologous melanoma cells in vitro more effectively than equivalent amounts of rhIL-2 (14) . In this report, we demonstrate the ability of the chl4.18-IL-2 fusion protein to suppress the dissemination and growth of human neuroblastoma in experimental hepatic metastases of severe combined immunodeficiency (scid) mice in the presence ofhuman LAK cells and to prolong the life-span of these animals. Our results indicate that the chl4.18-IL-2 fusion protein is considerably more proficient in achieving these objectives than equivalent amounts of rhIL-2. These findings support our hypothesis that recombinant mAb-cytokine fusion proteins can specifically target cytokines to tumor sites and stimulate immune effector cells sufficiently to achieve efficient tumor cell lysis.
MATERIALS AND METHODS
Cytokine, Antibody, and Antibody-Cytokine Fusion Protein. rhIL-2 derived from Escherichia coli was a gift from Amgen Biologicals. Mouse/human chimeric anti-ganglioside GD2 antibody chl4.18 has been described (10, 15 (Fig. 2) . Essentially the same amount of lysis was obtained in three separate experiments done at identical effector/target cell ratios (5:1) with antibody concentrations of 0.1, 1, and 10 ,ug/ml, respectively (data not shown).
Biodistribution of Human LAK Cells in scid Mice. The biodistribution and time of survival of human LAK cells injected into scid mice was determined to evaluate their potential in mediating in vivo lysis of, SK-N-AS cells coated with either chl4.18 or chl4.18-IL-2. Human peripheral blood lymphocytes, incubated with rhIL-2 for 72 hr and then labeled with 51Cr, were injected i.p. into scid mice. Approximately 20% of the total radioactivity injected was detected 48 hr later in the liver of these animals, suggesting that injected LAK cells localize, in part, to the major metastasis site in our model (data not shown).
Hepatic Metastasis of SK-N-AS. Upon intrasplenic injection of SK-N-AS cells and excision of the spleen, hepatic metastases were found in 100%6 of the scid mice 4 weeks postinjection. Lymph node involvement was not detected in any of these animals. The presence of metastatic neuroblastoma in the liver was confirmed by histological examination and demonstrated to be distributed throughout the hepatic parenchyma (data not shown). As depicted in Fig. 3 , in the majority of these animals, most of the liver tissue was replaced by tumor.
Suppression of Hepatic NeuroblsUna Metastases in scid Mice. The results of studies designed to critically assess the efficacy of the chl4.18-IL-2 fusion protein in suppressing dissemination and growth of hepatic neuroblastoma metastases in scid mice are summarized in Table 1 . There was a lack of a statistically significant difference from controls in the number of hepatic metastases found in scid mice treated with either PBS or LAK cells. Most of these animals presented with a very large number (>500) of metastatic foci in their livers that was not possible to count accurately and exhibited up to 3-fold greater liver weights than untreated animals. Although scid mice treated with LAK cells plus chl4.18 showed a statistically significant decrease (P = 0.01) in the number of metastatic foci, all of these animals presented with metastases ranging from 5 to 100 liver foci and had increased liver weights. In contrast, all scid mice treated with the chl4.18-IL-2 fusion protein revealed a complete absence of macroscopic metastatic liver foci (P = 0.003) and also presented with normal liver weights. However, when scid mice were treated with a mixture of chl4.18 and rhIL-2 at dose levels equivalent to the chl4.18-IL-2 fusion protein, they also showed a complete lack of macroscopic metastatic liver foci (Table 1) . Identical results were obtained when scid mice were treated with high doses (7.5 x 105 IU/day) of rhIL-2 per se (data not shown). Since we observed these same effects with both chl4.18-IL-2 and a mixture ofchl4.18 and rhIL-2 at these relatively high dose levels-i.e., 250 pg of chl4.18-IL-2-we compared their effect at lower dose levels. As shown in Table 2 , as little as 1 ,g of chl4.18-IL-2 per injection proved effective in suppressing dissemination and growth of metastasis. Indeed, dose levels of 1, 8, and 16 ,.g of ch14.18-IL-2 fusion protein were far more capable in suppressing growth of tumor metastasis than equivalent doses of rhIL-2. Moreover, another set of experiments indicated that relatively low dose levels of chl4.18-IL-2 (1 and 16 pg) were also more proficient than equivalent amounts of rhIL-2 (3000 and 48,000 IU) in prolonging the life-span of tumor-bearing scid mice reconstituted with human LAK cells (Table 3) .
DISCUSSION
The application of recombinant DNA technology has recently led to the construction of antibody-cytokine fusion proteins designed to achieve optimal biological effectiveness by combining the unique targeting ability of antibodies with the multifunctional activities of cytokines (14, 19, 20) . Antibody-cytokine fusion proteins have been proposed for the treatment of solid tumors, including melanoma (14) and Table 1 . Effect of a chl4.18-IL-2 fusion protein on experimental metastasis of SK-N-AS neuroblastoma cells in scid mice reconstituted with human LAK cells Liver metastases Treatment* No. of focit P value Liver wt,* g Control (PBS) 500 (250, 300, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500) 3.06 ± 1.3 LAK 500 (2, 500, 500, 500, 500, 500, 500) 0. carcinoma (21, 22) . Furthermore, antibody-cytokine fusion proteins may also be used as a cancer vaccine, as has been demonstrated in a model for B-cell lymphoma (23) .
Here, we evaluated an antibody-cytokine fusion protein, chl4.18-IL-2, for its ability to suppress dissemination and growth of human neuroblastoma in a preclinical model. Our primary aim was to test the hypothesis that this fusion protein can specifically target rhIL-2 to tumor sites and is more effective than rhIL-2 in achieving efficient tumor cell lysis. We could demonstrate that this was the case in an experimental hepatic metastasis model for human neuroblastoma in scid mice reconstituted with human LAK cells. In this experimental model, the chl4.18-IL-2 fusion protein was also more proficient than equivalent doses of rhIL-2 in prolonging the life-span of these animals. 18 in suppressing growth of human neuroblastoma metastasis in scid mice. However, it was particularly impressive that the fusion protein can achieve this effect at very low dose levels (1 yg per injection) and more effectively than equivalent amounts of rhIL-2. These findings are encouraging for two reasons. First, they strongly support our hypothesis that recombinant antibody-cytokine fusion proteins can specifically target cytokines to tumor sites and stimulate immune effector cells sufficiently to achieve efficient tumor cell lysis. Second, the fact that very low dose levels of the chl4.18-IL-2 fusion protein proved more effective than equivalent amounts of rhIL-2 in suppressing tumor growth in scid mice and in prolonging their life-span suggests that it may also be feasible to apply an optimal biological dose of chl4.18-IL-2 for future treatment of pediatric neuroblastoma patients. Third, based on our data, one might anticipate that the potentially lower effective dose levels of chl4.18-IL-2 may produce less toxicity than the relatively high dose levels of rhIL-2 necessary to achieve anti-tumor effects in clinical applications.
In summary, we demonstrated here that the chl4.18-IL-2 fusion protein can effectively suppress dissemination and growth of hepatic metastasis of human neuroblastoma in scid mice reconstituted with human LAK cells. This antibodycytokine fusion protein was shown to be superior in this regard to an equivalent dose of rhIL-2 and also proved more capable in prolonging the life-span ofthese animals. Although we realize the limitations of our experimental metastasis model in scid mice in terms of its predictive value for the eventual clinical effectiveness of chl4.18-IL-2, we believe that this recombinant fusion protein may hold some promise for future treatment of human neuroblastoma and other GD2-expressing tumors in an adjuvant setting.
